BTAI:NSD-BioXcel Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 51.49

Change

0.00 (0.00)%

Market Cap

USD 1.25B

Volume

0.41M

Average Target Price

USD 99.00 (+92.27%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent for the treatment of prostate and pancreatic cancers, and other solid tumors. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA; Nektar Therapeutics, Inc.; and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.

Company Website : http://www.bioxceltherapeutics.com

Address : 555 Long Wharf Drive, New Haven, CT, United States, 06511

Employees : 40

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.29

52 Week High : 65.66

Short Ratio : 7.79

52 Week Low : 13.77

Shorted Shares : 3,329,690

200 Day Moving Average : 48.08

Shorted Shares Previous Month : 3,189,029

50 Day Moving Average : 48.76

Shares Held By Insiders : 397.98%

Short Percentage : 14.00%

Shares Held by Institutions : 53.92%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD58.65B 22.10 18.26
REGN Regeneron Pharmaceuticals, Inc

N/A

 USD55.27B 18.98 14.64
MRNA Moderna, Inc

N/A

 USD51.30B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

 USD34.27B 36.37 33.83
SGEN Seagen Inc

N/A

 USD33.25B 70.15 70.76
RPRX Royalty Pharma plc

N/A

 USD32.48B 22.60 11.90
BGNE BeiGene, Ltd

N/A

 USD31.01B N/A N/A
GMAB Genmab A/S

N/A

 USD28.71B 26.59 3.08
BNTX BioNTech SE

N/A

 USD24.46B -99,999.99 N/A
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing BTAI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.45% 55% F 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.45% 55% F 71% C-
Trailing 12 Months  
Capital Gain 208.88% 91% A- 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 208.88% 91% A- 93% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 147.59% 94% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 147.59% 94% A 97% A+
Risk Return Profile  
Volatility (Standard Deviation) 236.43% 8% F 4% F
Risk Adjusted Return 62.42% 87% B+ 79% C+
Market Capitalization 1.25B 76% C 67% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 5.68 44% F 29% F
Price / Cash Flow Ratio -45.99 88% B+ 91% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -54.32% 59% F 21% F
Return on Invested Capital -102.16% 25% F 9% F
Return on Assets -30.30% 44% F 12% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 7.79 20% F 13% F
Short Percent 22.70% 6% F 9% F
Beta 1.29 63% D 42% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.